With the three healthcare stocks featured below, any “buying the dip” in them today could prove to be a regretful mistake in hindsight.<\/p>\n
1. Moderna<\/p>\n
Moderna (MRNA<\/a> +0.95%), a longtime biotech start-up, became a highly profitable drug company in 2021 and 2022, when Spikevax, its COVID-19 vaccine, was in high demand due to the pandemic. In both those years, additional revenue and earnings were in the billions.<\/p>\n Image source: Getty Images.<\/p>\n Since then, however, COVID-19 vaccine demand dropped dramatically, and revenue has fallen significantly. Last quarter, Moderna’s total sales totaled just $142 million. Meanwhile, the company continues to invest heavily into the development of other mRNA-based medicines, but these costly efforts have yet to produce Moderna’s next blockbuster drug<\/a>.<\/p>\n Givern these circumstances, it’s not surprising that share prices have fallen by around 35% year to date, and by around 95% from their all-time highs set in 2021. Unless Moderna unveils a positive surprise when the company next announces earnings on Nov. 6, shares could experience further downward price pressure.<\/p>\n Today’s Change<\/p>\n (0.95%) $0.26<\/p>\n Current Price<\/p>\n $27.50<\/p>\n Key Data Points<\/p>\n Market Cap<\/p>\n $11B<\/p>\n Day’s Range<\/p>\n $26.65 – $27.58<\/p>\n 52wk Range<\/p>\n $23.15 – $57.69<\/p>\n Volume<\/p>\n 220K<\/p>\n Avg Vol<\/p>\n 10M<\/p>\n Gross Margin<\/p>\n 45.74%<\/p>\n Dividend Yield<\/p>\n N\/A<\/p>\n 2. Novo Nordisk<\/p>\n Novo Nordisk (NVO<\/a> 1.78%) once had first-mover advantage<\/a> when it came to GLP-1 therapies, but competitors like Eli Lilly have since grabbed significant market share. As a result, forecasts call for this company, the manufacturer of Ozempic and Zepbound, to experience a slowdown in earnings growth this year, as well as in 2026.<\/p>\n While earnings per share increased by 22% in 2024, sell-side analyst<\/a> estimates say that earnings will only increase 3.8% this year, and by 4.8% in 2026. Worse yet, recent remarks from President Donald Trump regarding GLP-1 prices could mean even greater disappointment with future earnings.<\/p>\n Trading at a forward P\/E ratio of 14, Novo Nordisk might look like a “cheaper way” to play the GLP-1 trend, given that Eli Lilly trades for 27 times forward earnings. However, relative to growth, Novo Nordisk’s valuation isn’t justified, and it may be somewhat inflated, especially if governmental pressure to lower GLP-1 prices does indeed start to affect profitability and growth.<\/p>\n Today’s Change<\/p>\n (-1.78%) $-0.99<\/p>\n Current Price<\/p>\n $54.75<\/p>\n Key Data Points<\/p>\n Market Cap<\/p>\n $188B<\/p>\n Day’s Range<\/p>\n $54.54 – $55.36<\/p>\n 52wk Range<\/p>\n $45.05 – $116.65<\/p>\n Volume<\/p>\n 329K<\/p>\n Avg Vol<\/p>\n 18M<\/p>\n Gross Margin<\/p>\n 83.94%<\/p>\n Dividend Yield<\/p>\n 0.03%<\/p>\n 3. UnitedHealth Group<\/p>\n![\"people](\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2025\/10\/research-scientists-drugs-pharma-biotech.jpg\"\/)
<\/p>\n<\/p>\n
<\/p>\n